Trial Profile
Imatinib mesylate versus allogeneic HSCT for patients with chronic myelogenous leukemia
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 May 2012
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 23 May 2012 New trial record